Klein Christian, Wüstefeld Torsten, Assmus Ulrike, Roskams Tania, Rose-John Stefan, Müller Michael, Manns Michael P, Ernst Mattias, Trautwein Christian
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
J Clin Invest. 2005 Apr;115(4):860-9. doi: 10.1172/JCI23640. Epub 2005 Mar 3.
Increasing evidence demonstrates that IL-6 has a protective role during liver injury. IL-6 activates intracellular pathways via the gp130 receptor. In order to identify IL-6-gp130 pathways involved in mediating liver protection, we analyzed hepatocyte-specific gp130 knockout mice in a concanavalin A-induced (Con A-induced) model of immune-mediated hepatitis. We demonstrated that IL-6-gp130-dependent pathways in hepatocytes alone are sufficient for triggering protection in Con A-induced hepatitis. gp130-STAT3 signaling in hepatocytes mediates the IL-6-triggered protective effect. This was demonstrated by analysis of IL-6-induced protection in mice selectively deficient for gp130-dependent STAT1/3 or gp130-SHP2-RAS signaling in hepatocytes. To identify IL-6-gp130-STAT1/3 dependently expressed liver-protective factors, we performed gene array analysis of hepatic gene expression in hepatocyte-specific gp130(-/-) mice as well as in gp130-STAT1/3- and gp130-SHP2-RAS-MAPK-deficient mice. The mouse IL-8 ortholog KC (also known as Gro-alpha) and serum amyloid A2 (SAA2) was identified as differentially IL-6-gp130-STAT3-regulated genes. Hepatic expression of KC and SAA2 mediate the liver-protective potential of IL-6, since treatment with recombinant KC or serum SAA2 effectively reduced liver injury during Con A-induced hepatitis. In summary, this study defines IL-6-gp130-STAT3-dependent gene expression in hepatocytes that mediates IL-6-triggered protection in immune-mediated Con A-induced hepatitis. Additionally, we identified the IL-6-gp130-STAT3-dependent proteins KC and SAA2 as new candidates for therapeutic targets in liver diseases.
越来越多的证据表明,白细胞介素-6(IL-6)在肝损伤过程中具有保护作用。IL-6通过糖蛋白130(gp130)受体激活细胞内信号通路。为了确定参与介导肝脏保护的IL-6-gp130信号通路,我们在刀豆蛋白A诱导的(Con A诱导的)免疫介导性肝炎模型中分析了肝细胞特异性gp130基因敲除小鼠。我们证明,仅肝细胞中的IL-6-gp130依赖性信号通路就足以在Con A诱导的肝炎中触发保护作用。肝细胞中的gp130-信号转导和转录激活因子3(STAT3)信号传导介导IL-6触发的保护作用。这通过分析在肝细胞中选择性缺乏gp130依赖性信号转导和转录激活因子1/3(STAT1/3)或gp130-含Src同源2结构域蛋白2(SHP2)-RAS信号传导的小鼠中IL-6诱导的保护作用得以证明。为了鉴定IL-6-gp130-STAT1/3依赖性表达的肝脏保护因子,我们对肝细胞特异性gp130基因敲除小鼠以及gp130-STAT1/3和gp130-SHP2-RAS-丝裂原活化蛋白激酶(MAPK)缺陷小鼠的肝脏基因表达进行了基因芯片分析。小鼠IL-8直系同源物角质形成细胞趋化因子(KC,也称为Gro-α)和血清淀粉样蛋白A2(SAA2)被鉴定为受IL-6-gp130-STAT3差异调节的基因。KC和SAA2的肝脏表达介导了IL-6的肝脏保护潜能,因为用重组KC或血清SAA2治疗可有效减轻Con A诱导的肝炎期间的肝损伤。总之,本研究确定了肝细胞中IL-6-gp130-STAT3依赖性基因表达,其介导了免疫介导的Con A诱导的肝炎中IL-6触发的保护作用。此外,我们鉴定出IL-6-gp130-STAT3依赖性蛋白KC和SAA2作为肝病治疗靶点的新候选物。